Biotech and Pharma Industry News | BioPharma Dive
WEBSpun out of research at Nationwide Children’s Hospital, Vironexis claims it will be the first company to start a study testing a cancer drug delivered via the adeno-associated viruses commonly used in genetic medicines. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
10 clinical trials to watch in the first half of 2022
WEBJan 3, 2022 · Over the course of 2022, study results from Roche and Eisai could offer supporting evidence for Aduhelm, its developer Biogen and the FDA, or throw the drug’s approval further into doubt. Aduhelm, Roche’s gantenerumab and Eisai’s lecanemab all work by targeting clumps of a protein in the brain known as amyloid.
Drugging RNA with pills: small molecules for a big frontier
WEBPublished Sept. 6, 2022. Gwendolyn Wu Reporter. A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule. Christoph Burgstedt via Getty Images. Editor’s note: BioPharma Dive, as part of its newly launched Emerging Biotech Weekly, is taking a closer look at competitive areas of startup activity.
Paper details Astellas gene therapy study that led to patient deaths
WEBNov 16, 2023 · A new paper published online in The Lancet Neurology Wednesday provides key new details on a gene therapy study that left four patients dead and posed broader questions about safety for the emerging field.. The article lays out data from the so-called Aspiro trial of Astellas Pharma’s AT132, a therapy designed to treat X-linked myotubular myopathy, a rare neuromuscular condition that almost ...
Astellas joins gene therapy race with $3B Audentes buy
WEBDec 3, 2019 · Dive Insight: Astellas is paying up to join the gene therapy race. At $60 per share, the Japanese pharma's takeover offer is more than double the $28.61 at which shares in Audentes traded at Monday's market close — a multiple on par with Roche's bid for Spark but higher than the premium Novartis …
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEBSep 16, 2024 · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
Biotech M&A has plateaued. Track the deals that are happening …
WEB5 days ago · Inside the market of emerging biotech. New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at …
Novartis sees brighter sales future as R&D revamp continues
WEBNov 28, 2023 · In a presentation Tuesday, the Swiss pharmaceutical company told investors that it expects sales to grow at a 5% compound annual rate between 2022 and 2027, up from the 4% rate it had previously set. That’s still below the 7% growth Novartis reported over the prior five years, however. The upgrade comes as …
10 clinical trials to watch in the second half of 2022
WEBJul 5, 2022 · The second half of the year could bring similarly important results from clinical trials testing drugs for Alzheimer’s disease, cancer and vision loss. Positive data, if it comes, might give biotech a needed boost. Here are 10 trials to watch: Companies: Eisai, Biogen. Disease: Alzheimer’s. Treatment type:
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Skip to content